Table 1 The table indicates the ongoing or completed phase 2/3 clinical trials of OVs. Clinical Trials search filters: “Recruitment: Recruiting and completed. Study type: Interventional. Study result: All. Study Phase:2/3/4.” Source: https://clinicaltrials.gov/. Jun 2022

Intraperitoneal injection of oncolytic viruses H101 for patients with refractory malignant ascites

Drug: oncorine (H101)

Refractory malignant ascites

2

NCT04771676

OH2 oncolytic viral therapy in central nervous system tumors

Biological: OH2 injection

Central nervous system tumors

2

NCT05235074

Safety and efficacy of CG0070 oncolytic virus regimen for high grade NMIBC after BCG failure

Biological: CG0070

Bladder cancer

2

NCT02365818

A study of combination with TBI-1401(HF10) and ipilimumab in Japanese patients with unresectable or metastatic melanoma

Biological: TBI-1401(HF10) drug: ipilimumab

Melanoma stage III melanoma stage IV

2

NCT03153085

A study of combination treatment with HF10 and ipilimumab in patients with unresectable or metastatic melanoma

Biological: HF10 plus ipilimumab

Malignant melanoma

2

NCT02272855

INCMGA00012 and pelareorep for the treatment of metastatic triple negative breast cancer, IRENE study

Biological: pelareorep

Anatomic stage IV breast cancer AJCC v8

2

NCT04445844

LOAd703 oncolytic virus therapy for pancreatic cancer

Genetic: delolimogene mupadenorepvec drug:gemcitabine drug:nabpaclitaxel biological:atezolizumab

Pancreatic cancer

2

NCT02705196

OH2 oncolytic viral therapy in pancreatic cancer

Biological:OH2 injection (OHSV-2)

Pancreatic cancer

2

NCT04637698

OH2 oncolytic viral therapy in solid tumors

Biological:OH2 injection, with or without irinotecan or HX008

Solid tumor gastrointestinal cancer

2

NCT03866525

OH2 injection in combination with HX008 for melanoma

Biological: OH2 injection, HX008 injection

Melanoma

2

NCT04616443

OH2 injection in solid tumors

Biological: OH2 injection Drug: Keytruda

Solid tumor melanoma

2

NCT04386967

A study of recombinant vaccinia virus to treat malignant melanoma

Biological: JX-594

Melanoma

2

NCT00429312

Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiform

Drug: H-1PV

Glioblastoma multiform

2

NCT01301430

Safety and efficacy study of REOLYSIN® in the treatment of bone and soft tissue sarcomas metastatic to the lung

Biological: REOLYSIN®

Osteosarcoma ewing sarcoma family tumors malignant fibrous histiocytoma

2

NCT00503295

A study of talimogene laherparepvec in stage IIIc and stage IV malignant melanoma

Drug: talimogene laherparepvec

Melanoma

2

NCT00289016

Study evaluating cemiplimab alone and combined with RP1 in treating advanced squamous skin cancer

Drug: cemiplimab Biological: RP1

Cutaneous squamous cell carcinoma advanced cutaneous squamous cell carcinoma metastatic cutaneous squamous cell carcinoma

2

NCT04050436

Study of RP1 monotherapy and RP1 in combination with nivolumab

Biological: RP1

Biological: nivolumab

Cancer melanoma (skin) mismatch repair deficiency

2

NCT03767348

A Study of GL-ONC1, an oncolytic vaccinia virus, in patients with advanced peritoneal carcinomatosis

Biological: GL-ONC1

Peritoneal carcinomatosis

2

NCT01443260

A study to assess overall response rate by inducing an inflammatory phenotype in metastatic BReast cAnCEr with the oncolytic reovirus PeLareorEp in combination with anti-PD-L1 avelumab and paclitaxel—BRACELET-1 study

Drug: paclitaxel Biological: pelareorep Drug: avelumab

Breast cancer metastatic

2

NCT04215146

A phase 2b study of modified vaccinia virus to treat patients advanced liver cancer who failed sorafenib

Biological: JX-594 Recombinant Vaccina GM-CSF other: best supportive car

Hepatocellular carcinoma liver cancer HCC

2

NCT01387555

A study of recombinant vaccinia virus to treat unresectable primary hepatocellular carcinoma

Genetic: JX-594: recombinant vaccinia virus (TK-deletion plus GM-CSF)

Carcinoma, hepatocellular

2

NCT00554372

Hepatocellular carcinoma study comparing vaccinia virus based immunotherapy plus sorafenib vs sorafenib alone

Biological: pexastimogene devacirepvec (Pexa Vec)

Drug: sorafenib

Hepatocellular carcinoma (HCC)

2

NCT02562755

Phase 2 study of REOLYSIN® in combination with paclitaxel and carboplatin for non-small cell lung cancer with KRAS or EGFR activation

Biological: REOLYSIN® drug: carboplatin drug: paclitaxel

Carcinoma, non-small cell lung

2

NCT00861627

Study of TBio-6517 Given alone or in combination with pembrolizumab in solid tumors

Biological: TBio-6517 biological: pembrolizumab

Solid tumor microsatellite stable colorectal cancer HPV positive oropharyngeal squamous cell carcinoma

2

NCT04301011

Intrapleural administration of HSV1716 to treat patients with malignant pleural mesothelioma

Biological: HSV1716 intra-pleural delivery

Malignant pleural mesothelioma

2

NCT01721018

Oncolytic MG1-MAGEA3 with Ad-MAGEA3 vaccine in combination with pembrolizumab for non-small cell lung cancer patients

Biological: BT-001 biological: pembrolizumab [Keytruda]

Solid tumor, adult metastatic cancer soft tissue sarcoma

2

NCT02879760

A clinical trial assessing BT-001 alone and in combination with pembrolizumab in metastatic or advanced solid tumors

Biological: BT-001

biological: pembrolizumab [keytruda]

Solid tumor, adult metastatic cancer soft tissue sarcoma

2

NCT04725331

Recombinant vaccinia virus administered intravenously in patients with metastatic, refractory colorectal carcinoma

Biological: JX-594 drug: irinotecan

Colorectal carcinoma CRC

2

NCT01394939

UARK 2014–21 a phase II Trial of oncolytic virotherapy by systemic administration of edmonston strain of measles virus

Drug: MV-NIS

Multiple myeloma

2

NCT02192775

Safety, tolerability and pharmacokinetics characteristics of recombinant oncolytic vaccinia virus injection t601 as a single drug or in combination with oral flucytosine (5-FC), in patients with advanced malignant solid tumors

Biological: T601

combination product: T601 + 5-FC

Advanced malignant solid tumors

2

NCT04226066